Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Video Interview: F-star CEO Details Asset-Centric Ambitions

This article was originally published in Scrip

Executive Summary

Unveiling its second asset-centric deal, F-star CEO Dr. John Haurum reveals to Mike Ward, global director of content for Informa's pharma insights products, how the company is looking to raise an additional $30m this year to help the company move some of its own programs into the clinic within 18 months. Dr. Haurum describes differences in the deals involving F-star alpha, an option deal with Bristol-Myers Squibb, and F-star beta which will see AbbVie get access to assets that will allow it to create bispecific antibodies targeting two particular immuno-oncology checkpoints.

Advertisement

Related Content

Denali Deal & F-star’s Innovative Asset Centric Business Model
Advertisement
UsernamePublicRestriction

Register

SC064730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel